This minimally invasive surgical therapy combines mechanical dilation with concurrent localized delivery of paclitaxel for treating benign prostatic hyperplasia (BPH) and urethral strictures. While Optilume is used for both BPH and strictures, the specific application of the device may differ slightly depending on the condition, primarily in how the balloon is positioned to target the affected area within the urethra. For BPH, the focus is on widening the space between the prostate lobes. For strictures, the goal is to open up a narrowed section of the urethra itself, all while utilizing the same drug-coated balloon technology to prevent tissue regrowth.
Both treatments use a drug-coated balloon to dilate the urethra, but for BPH, the balloon is positioned to separate the prostate lobes, while for strictures, it is placed directly at the narrowed section of the urethra. The drug coating on the balloon is the same for both conditions, typically paclitaxel, which helps to inhibit cell proliferation and prevent scar tissue formation, reducing the risk of recurrence.
How is Optilume different?
- One-time procedure that takes 15 minutes to perform.
- Requires no hospital stay or a lengthy recovery period.
- No ongoing treatments necessary.
- 75% success rate with nearly 0% serious complications.
- In most cases, Optilume provides immediate relief.
The Optilume BPH Catheter System is a drug-coated balloon that is inserted into the urethra via a telescopic camera, to the prostate. Once in the prostate, the balloon expands creating an opening, and releases the safe and proven drug, paclitaxel, into the open prostate. When the drug coating is fully released, the balloon is deflated and removed. The applied drug prevents re-fusion of the lobes during healing, keeping the prostate open, restoring the flow of urine, and relieving your symptoms.
Why choose Optilume BPH?
- Clinical studies show Optilume BPH is safe and effective.
- Highest clinically reported flow rates of any minimal invasive therapy.
- Immediate and durable symptom relief.
- Minimal catheter time.
- No impact on sexual function.
- Quick recovery.
- In-office or outpatient procedure.
- No cutting. No heating. No burning. No lasering. No steaming. No implantation!
Current endoscopic anterior urethral stricture treatments are common practice and often ineffective, leading to multiple repeat procedures with diminishing results. Optilume is an effective alternative to traditional endoscopic structure treatments, offering minimally invasive, immediate relief. Optilume works by inhibiting new scar tissue growth that often recurs after dilations or direct visual internal urethrotomy. Paclitaxel, the drug that coats the balloon, is a proven antiproliferative drug that has been effectively used in millions of patients worldwide since the early 1990s.
References:
